Pneumo Care’s focus will be to sell the PulmoTrack and the WheezoMeter in both the private patient market and doctor’s surgeries. Pneumo Care in conjunction with KSX has also developed a continuous revenue model for the upcoming release of the ambulatory monitoring device, the WHolter.

The WHolter allows the physician to obtain data relating to wheeze detection, cough detection, and respiratory rate in the patient’s home environment. KarmelSonix has received an initial commitment for the placement of 100 WheezoMeters plus PulmoTracks and Wholters.

Paul Eisen, managing director of Europe and Asia Pacific at KSX, said: “Partnering with Pneumo Care represents our growth opportunity in the Asia Pacific region. Along with Sapco Laboratories in South India, we now have complete geographic coverage of India with a committed sales force of over 50 staff on the ground.

“My work with Pneumo Care over many years in rapidly developing the sleep disordered breathing market for ResMed, gives me great confidence as we approach we will do the same in the asthma management field with this unique technology.”

Parveen Nayar, director of Pneumo Care, said: “With 20 years experience in the Indian respiratory market, we know we can successfully introduce KarmelSonix’s unique technology into a market where more than 40 million people suffer from asthma.”